AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (Original) A composition comprising a glucocorticoid and at least one phosphodiesterase-4 inhibitor in fixed or free combination.

2. (Original) The composition as claimed in claim 1, characterized in that the phosphodiesterase-4 inhibitor is rolipram, piclamilast, roflumilast, cilomilast, the hydroxyindole derivative N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO) or their pharmaceutically acceptable salts or mixtures thereof.

3. (Currently amended) The composition as claimed in ~~either of~~ claim[[s]] 1 [[or 2]], characterized in that the glucocorticoid is a soft steroid.

4. (Currently amended) The composition as claimed in ~~any of~~ claim[[s]] 1 [[to 3]], characterized in that the glucocorticoid is beclomethasone, budesonide, ciclesonide, fluticasone, mometasone or loteprednol or a pharmaceutically acceptable ester thereof.

5. (Currently amended) The composition as claimed in claim 3 [[or 4]], characterized in that the glucocorticoid is loteprednol etabonate.

6. (Original) A medicament for the treatment of respiratory diseases, allergic diseases, asthma and/or chronic obstructive pulmonary diseases, comprising as active ingredient a glucocorticoid

and at least one phosphodiesterase-4 inhibitor in fixed or free combination, where appropriate together with customary excipients or carriers.

7. (Original) The medicament as claimed in claim 6, characterized in that it can be administered orally.

8. (Original) The medicament as claimed in claim 6, characterized in that it can be administered topically.

9. (Original) The medicament as claimed in claim 8, characterized in that it can be administered simultaneously, sequentially or separately from one another, intranasally or by inhalation.

10. (Currently amended) The medicament as claimed in claim 8 [[or 9]], characterized in that it is an inhalable liquid or solid preparation.

11. (Original) The medicament as claimed in claim 6, characterized in that one active ingredient is administered orally and at least one active ingredient is administered topically.

12.(Original) The medicament as claimed in claim 6, characterized in that the phosphodiesterase-4 inhibitor(s) can be administered orally.

13. (Original) A process for producing a medicament for the treatment and prophylaxis of respiratory diseases, allergic diseases, asthma and/or chronic obstructive pulmonary diseases, comprising as active ingredient a glucocorticoid and at least one phosphodiesterase-4 inhibitor, characterized in that the glucocorticoid and the phosphodiesterase-4 inhibitor(s) are mixed singly or together, where appropriate together with customary excipients and carriers, and the mixture obtained in this way is converted into suitable dosage forms.

14. (Original) The use of the fixed or free combination of a glucocorticoid and at least one phosphodiesterase-4 inhibitor for producing a medicament for the treatment and prophylaxis of respiratory diseases, allergic diseases, asthma and/or chronic obstructive pulmonary diseases.

15. (Original) The use as claimed in claim 14, characterized in that the glucocorticoid is loteprednol etabonate and the phosphodiesterase-4 inhibitor is the hydroxindole derivative N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide (DFHO).